Daniel V Dudenkov1, Barbara P Yawn2, Sara S Oberhelman3, Philip R Fischer4, Ravinder J Singh5, Stephen S Cha6, Julie A Maxson3, Stephanie M Quigg3, Tom D Thacher3. 1. Department of Internal Medicine, Mayo Clinic, Rochester, MN. Electronic address: dudenkov.daniel@mayo.edu. 2. Olmsted Medical Center, Rochester, MN. 3. Department of Family Medicine, Mayo Clinic, Rochester, MN. 4. Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN. 5. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN. 6. Department of Health Science Research, Mayo Clinic, Rochester, MN.
Abstract
OBJECTIVE: To determine the incidence trend of 25-hydroxyvitamin D (25(OH)D) values above 50 ng/mL and associated toxicity. PATIENTS AND METHODS: We conducted a retrospective population-based study in Olmsted County, Minnesota, in the 10-year period from January 1, 2002, through December 31, 2011, by using the Rochester Epidemiology Project. Individuals were eligible if they resided in Olmsted County during the study period and had a measured 25(OH)D value above 50 ng/mL. The date of the first 25(OH)D value above 50 ng/mL was considered the index date for incidence determination. Hypercalcemia, the primary vitamin D toxicity, was considered potentially associated with the 25(OH)D concentration if it was measured within 3 months of the 25(OH)D measurement, and such cases had a medical record review. RESULTS: Of 20,308 total 25(OH)D measurements, 1714 (8.4%), 123 (0.6%), and 37 (0.2%) unique persons had 25(OH)D values above 50, 80 and above, and 100 ng/mL and above, respectively. The age- and sex-adjusted incidence of 25(OH)D values above 50 ng/mL increased from 9 to 233 cases per 100,000 person-years from 2002 to 2011 (P<.001), respectively, and was greatest in persons aged 65 years and older (P<.001) and in women (P<.001). Serum 25(OH)D values were not significantly related to serum calcium values (P=.20) or with the risk of hypercalcemia (P=.24). A medical record review identified 4 cases (0.2%) in whom 25(OH)D values above 50 ng/mL were temporally associated with hypercalcemia, but only 1 case had clinical toxicity associated with the highest observed 25(OH)D value of 364 ng/mL. CONCLUSION: The incidence of 25(OH)D values above 50 ng/mL increased significantly between 2002 and 2011 without a corresponding increase in acute clinical toxicity.
OBJECTIVE: To determine the incidence trend of 25-hydroxyvitamin D (25(OH)D) values above 50 ng/mL and associated toxicity. PATIENTS AND METHODS: We conducted a retrospective population-based study in Olmsted County, Minnesota, in the 10-year period from January 1, 2002, through December 31, 2011, by using the Rochester Epidemiology Project. Individuals were eligible if they resided in Olmsted County during the study period and had a measured 25(OH)D value above 50 ng/mL. The date of the first 25(OH)D value above 50 ng/mL was considered the index date for incidence determination. Hypercalcemia, the primary vitamin Dtoxicity, was considered potentially associated with the 25(OH)D concentration if it was measured within 3 months of the 25(OH)D measurement, and such cases had a medical record review. RESULTS: Of 20,308 total 25(OH)D measurements, 1714 (8.4%), 123 (0.6%), and 37 (0.2%) unique persons had 25(OH)D values above 50, 80 and above, and 100 ng/mL and above, respectively. The age- and sex-adjusted incidence of 25(OH)D values above 50 ng/mL increased from 9 to 233 cases per 100,000 person-years from 2002 to 2011 (P<.001), respectively, and was greatest in persons aged 65 years and older (P<.001) and in women (P<.001). Serum 25(OH)D values were not significantly related to serum calcium values (P=.20) or with the risk of hypercalcemia (P=.24). A medical record review identified 4 cases (0.2%) in whom 25(OH)D values above 50 ng/mL were temporally associated with hypercalcemia, but only 1 case had clinical toxicity associated with the highest observed 25(OH)D value of 364 ng/mL. CONCLUSION: The incidence of 25(OH)D values above 50 ng/mL increased significantly between 2002 and 2011 without a corresponding increase in acute clinical toxicity.
Authors: Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Walter A Rocca Journal: Am J Epidemiol Date: 2011-03-23 Impact factor: 4.897
Authors: Anne C Looker; Christine M Pfeiffer; David A Lacher; Rosemary L Schleicher; Mary Frances Picciano; Elizabeth A Yetley Journal: Am J Clin Nutr Date: 2008-12 Impact factor: 7.045
Authors: Pentti Tuohimaa; Leena Tenkanen; Merja Ahonen; Sonja Lumme; Egil Jellum; Göran Hallmans; Pär Stattin; Sverre Harvei; Timo Hakulinen; Tapio Luostarinen; Joakim Dillner; Matti Lehtinen; Matti Hakama Journal: Int J Cancer Date: 2004-01-01 Impact factor: 7.396
Authors: Daniel V Dudenkov; Kristin C Mara; Tanya M Petterson; Julie A Maxson; Tom D Thacher Journal: Mayo Clin Proc Date: 2018-05-02 Impact factor: 7.616
Authors: Rosemary L Schleicher; Maya R Sternberg; David A Lacher; Christopher T Sempos; Anne C Looker; Ramon A Durazo-Arvizu; Elizabeth A Yetley; Madhulika Chaudhary-Webb; Khin L Maw; Christine M Pfeiffer; Clifford L Johnson Journal: Am J Clin Nutr Date: 2016-07-06 Impact factor: 7.045
Authors: Miyad Movassaghi; Simona Bianconi; Richard Feinn; Christopher A Wassif; Forbes D Porter Journal: Am J Med Genet A Date: 2017-08-10 Impact factor: 2.802
Authors: Sapna P Sadarangani; Inna G Ovsyannikova; Krista Goergen; Diane E Grill; Gregory A Poland Journal: Hum Vaccin Immunother Date: 2016-03-03 Impact factor: 3.452